Logo

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Share this
Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Janssen to Present Results of Imbruvica (ibrutinib)-based Combination Regimen as 1L Treatment for Chronic Lymphocytic Leukemia at ASCO

Shots:

  • Janssen to present new data from the fixed-duration cohort of P-II CAPTIVATE study- demonstrating 95% of patients treated with combined Imbruvica + Venetoclax were alive and progression-free @2yrs. with deep remissions were seen across all subgroups- including patients with high-risk CLL
  • Additionally- Janssen will present 7yrs. data from the RESONATE-2 study on PFS and OS benefits with single-agent Imbruvica- reinforcing the survival benefits and long-term tolerability of therapy for patients with CLL
  • The results of RESONATE-2 study supporting the long-term benefits of Imbruvica monothx. in 1L CLL- supporting the use of Imbruvica as SOC

  Ref: Janssen | Image: Janssen

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions